Scientists in France have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin. Based on these results, the scientists have developed a prognostic test. Commercialization is anticipated in 2011.
Jan 05, 2011 12:00 AM
—
www.sciencedaily.com